BladeOne Error [Compiling]:
Unable to save the file [/home/pai/public_html/app/tmp/domains/ca.proactiveinvestors.com/cache/views/blade/a043daa2b7c5f8999d145b15059f6ad6bca29f8e.bladec]. Check the compile folder is defined and has the right permission
logo-loader
viewCardiol Therapeutics

Cardiol Therapeutics chooses Worldwide Clinical Trial for their Phase II/III study of CardiolRx

Cardiol Therapeutics (TSE: CRDL-OTCQX: CRTPF) CEO David Elsley joined Steve Darling from Proactive with news the company has selected a contract research organization to conduct their Phase II/III trial studying the effectiveness of CardiolRx in COVID-19 patients.

Elsley telling Proactive why they chose Worldwide Clinical Trials and also some details about the trial.

Quick facts: Cardiol Therapeutics

Price: 4.19 CAD

TSX:CRDL
Market: TSX
Market Cap: $137.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cardiol Therapeutics named herein, including the promotion by the Company of Cardiol Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Cardiol Therapeutics sees positives for company after GW Pharma and Jazz...

Cardiol Therapeutics (TSE: CRDL- OTCQX: CRTPF) CEO David Elsley joined Steve Darling to offer his perspective on Jazz Pharmaceuticals acquiring GW Pharma for 7.2 billion dollars. Elsley talks about what that means for the CBD Pharma industry and what it could potentially mean for Cardiol...

3 weeks, 6 days ago

2 min read